Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : reaches agreement to postpone more glyphosate lawsuits for settlement talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2019 | 10:53am EST
FILE PHOTO: Protests ahead of German drug and crop chemical maker Bayer's annual general meeting

Germany's Bayer has agreed with plaintiffs to postpone its next two U.S. lawsuits over the alleged cancer-causing effects of its glyphosate-based weed killers to allow more time for talks on a settlement.

The company, which is facing 42,700 U.S. plaintiffs, is widely expected to eventually buy itself out of the litigation, with analysts currently estimating the size of a future settlement at $8-$12 billion.

Bayer agreed with the plaintiff to delay for about six months a case in the California Superior Court for Lake County scheduled for Jan. 15, a company spokesman said in a written statement.

A second case due to begin on Jan. 21 in the California Superior Court for Alameda County would also be postponed until a date yet to be determined.

Bayer said the postponements would provide more time for it and representatives of the plaintiffs to "engage constructively in the mediation process".

The company, which acquired the weed killer brands last year as part of a $63 billion takeover of Monsanto, has ruled out pulling the products from the U.S. market, citing regulators and extensive research which have found glyphosate to be safe.

It will early next year appeal to reverse the first three U.S. court rulings that awarded tens of millions of dollars to each plaintiff.

Other trials initially scheduled for this year have already been postponed.

(Reporting by Ludwig Burger; Editing by Kirsten Donovan)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
09:57aBAYER : confirms leading international position as a sustainable company taking ..
AQ
01/20BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
01/20Japan, U.S. lead survey's corporate climate change action 'A List'
RE
01/18Drugmakers slash prices to be eligible for China's bulk-buy program
RE
01/17Bayer could be close to Roundup settlement, mediator says
RE
01/17EUROPE : European shares touch all-time peak on cross-Atlantic trade optimism
RE
01/17A flurry of news in the global auto industry
01/16BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
01/16BAYER : and WuXi Biologics enter into an agreement on a Leverkusen drug product ..
PU
01/15China's 'market condition' caveat on U.S. ag purchases adds to trade deal dou..
RE
More news
Financials (EUR)
Sales 2019 43 974 M
EBIT 2019 7 853 M
Net income 2019 3 106 M
Debt 2019 35 649 M
Yield 2019 3,77%
P/E ratio 2019 24,5x
P/E ratio 2020 16,0x
EV / Sales2019 2,50x
EV / Sales2020 2,29x
Capitalization 74 173 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 81,28  €
Last Close Price 75,50  €
Spread / Highest target 62,9%
Spread / Average Target 7,66%
Spread / Lowest Target -48,7%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Florian Schwalbach Head-Information Technology & Business Services
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG3.69%82 204
JOHNSON & JOHNSON2.26%392 596
ROCHE HOLDING AG4.44%289 068
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS0.96%216 654